The National Institutes of Health (NIH) has awarded two-year small business innovation research (SBIR) grant of $582,473 to Biodel to develop a concentrated ultra-rapid-acting insulin formulations for use in closed loop pump system, also known as artificial pancreas.
The concentrated ultra-rapid-acting insulin formulations have prolonged duration of action for use with an artificial pancreas, absorbed more rapidly and are 5-times more concentrated than existing concentrated insulin formulations.
Biodel said regular insulin at concentrations of 500 units per milliliter is used to treat extremely insulin resistant patients with diabetes.
Biodel president and CEO Errol De Souza said the company is gratified to receive the award to develop novel therapies for the treatment for diabetes.
"These funds will be focused on applying our proprietary technology for the development of ultra-rapid-acting insulin formulations for the treatment of insulin resistant patients and to assist in the development of effective artificial pancreas therapy," Souza added.
